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activity. Our results demonstrate that non-steroidal Cpda, 
unlike classic steroidal GCs, blocks NF-κB- but not aP-1-
driven gene expression. Cpda rather sustains aP-1-driven 
gene expression, a result which could mechanistically be 
explained by the failure of Cpda to block upstream JNK 
kinase activation and concomitantly also phosphorylation 
of c-Jun. In concordance and in contrast to DeX, Cpda 
maintained the expression of the activated aP-1 target gene 
c-jun, as well as the production of the c-Jun protein. as for 
the underlying mechanism, GR is a necessary intermediate 
in the Cpda-mediated gene expression of aP-1-regulated 
genes, but seems to be superfluous to Cpda-mediated JNK 
Abstract Glucocorticoids (GCs) block inflammation via 
interference of the liganded glucocorticoid receptor (GR) 
with the activity of pro-inflammatory transcription factors 
NF-κB and aP-1, a mechanism known as transrepression. 
this mechanism is believed to involve the activity of GR 
monomers. here, we explored how the GR monomer-
favoring Compound a (Cpda) affects aP-1 activation and 
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phosphorylation prolongation. the latter phenomenon 
concurs with the inability of Cpda to stimulate DUSP1 
gene expression. ChIP analysis demonstrates that DeX-
activated GR, but not Cpda-activated GR, is recruited to 
aP-1-driven promoters. Furthermore, in mice we observed 
that Cpda instigates a strong enhancement of tNF-induced 
aP-1-driven gene expression. Finally, we demonstrate that 
this phenomenon coincides with an increased sensitivity 
towards tNF lethality, and implicate again a role for JNK2. 
In conclusion, our data support the hypothesis that a ligand-
induced differential conformation of GR yields a different 
transcription factor cross-talk profile.
Keywords Glucocorticoids · Inflammation · Mitogen-
activated protein kinase (MaPK) · Selective GR 
modulator · c-Jun · Jun N-terminal kinase (JNK)
Abbreviations
aP-1  activator protein 1
β-gal  β-Galactosidase
Cpda  Compound a
CReB  caMP-responsive element binding protein
DeX  Dexamethasone
DUSP1  dual-specificity phosphatase 1
eRK  extracellular signal-regulated kinase
GC  Glucocorticoid
GILZ  GC-induced leucine zipper
GR  Glucocorticoid receptor
GRe  GC response element
h  histone
IκB  Inhibitor of NF-κB
IL  Interleukin
i.p.  Intraperitoneally
IPa  Ingenuity pathway analysis
luc  Luciferase
JNK  Jun N-terminal kinase
MaPK  Mitogen-activated protein kinase
MCP1  Monocyte chemoattractant protein 1
MeF  Mouse embryonic fibroblast
MMP  Matrix metalloproteinase
MSK  Mitogen- and stress-activated protein kinase
NF-κB  Nuclear factor-κB
PBS  Phosphate-buffered saline
SGRM  Selective GR modulator
StS  Staurosporine
tNF  tumor necrosis factor
tPa  12-O-tetradecanoylphorbol-13-acetate
Introduction
the glucocorticoid receptor (GR, NR3C1) is a ligand-
dependent transcription factor belonging to the subfamily 
3C of the nuclear receptor superfamily [1]. GR comprises 
a N-terminal transactivation domain, a DNa-binding 
domain (DBD) and a C-terminal ligand-binding domain 
(LBD) [2, 3]. Classic GR target gene promoter activation 
occurs via interaction of homodimeric GR with specific 
GR-binding sequences (GBS) at glucocorticoid response 
elements (GRe) [4–6]. GR can also orchestrate transcrip-
tional networks via protein–protein interactions, resulting 
in a positive or negative transcriptional outcome, depending 
on the target gene and the cellular context [7]. the com-
plex mechanisms by which glucocorticoids (GCs) inhibit 
gene expression, of which transrepression has been best 
described, have always received the most attention, because 
they allow to explain a large part of the immunosuppressive 
action of GCs [6, 8].
the promoters of various genes coding for proteins 
involved in inflammatory processes, including cytokines, 
chemokines, and adhesion molecules harbor specific DNa 
sequences onto which the pro-inflammatory transcription 
factors NF-κB and/or aP-1 can bind. NF-κB, typically a 
heterodimer of p65 (Rela) and p50 (NF-κB1) Rel family 
members, predominantly resides in the cytoplasm in com-
plex with IκB inhibitory proteins. activation of the IKK 
complex leads it to phosphorylate the IκB inhibitory pro-
tein, marking it for subsequent degradation. hence, NF-
κB is released from its inhibitor, allowing its migration to 
the nucleus. Mitogen-activated protein kinases (MaPKs), 
eRK and p38, and downstream MaPK-activated proteins, 
including MSK1 additionally fine-tune its activity [9]. Vari-
ous stimuli, including cytokines (such as tNF-α) [10] and 
the microbial alkaloid staurosporine (StS) [11] result in 
the activation of nuclear NF-κB and/or aP-1, which con-
tact their regulatory DNa sequences and, as such, drive 
gene transcription of, e.g., the cytokine Interleukin-6 (IL-6) 
[12]. this cytokine has not only been implicated in immune 
regulation but also in endocrine and metabolic actions and 
aging. Understanding the regulation of this gene could con-
tribute to a controlled and tissue-restricted modulation of 
its pleiotropic action profile.
the c-jun proto-oncogene codes for c-Jun, which con-
stitutes together with c-Fos the prototypical dimeric aP-1 
transcription factor [13, 14]. Many pro-inflammatory 
genes are co-regulated by NF-κB and aP-1. however, an 
immediate early gene such as c-jun, is regulated by aP-1 
alone, and not by NF-κB. the activation of the c-Jun pro-
tein is rapidly regulated in response to a wide variety of 
external stimuli, including cytokines, tumor-promoting 
agents, UV irradiation, growth factors and hormones, and 
it does not require de novo protein synthesis [13, 15, 16]. 
Notably, aP-1 can bind to the c-jun gene promoter itself, 
thereby stimulating gene transcription via a feed-forward 
mechanism [17]. two regulatory aP-1 binding elements 
have been described in the c-jun gene promoter, a proximal 
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one and a distal one [17, 18]. Both aP-1 sites have been 
found to be susceptible to GR-mediated transrepression 
[15]. the Jun N-terminal kinase JNK is the most promi-
nent MaPK involved in the regulation of aP-1 [19]. Phos-
phorylation by JNK rapidly potentiates the transcriptional 
capacity of c-Jun, enhancing its ability to accommodate 
gene transcription, including its own [19]. In that respect, 
interactions between aP-1 and GC signaling pathways 
are not restricted to direct transcriptional interferences 
between GR and aP-1 [20]; GCs can also target the activ-
ity of JNK, which can be stimulated by pro-inflammatory 
cytokines, including tNF-α [21, 22].
Glucocorticoids (GCs) remain the gold standard in 
the treatment of chronic inflammatory diseases not only 
because they can efficiently relieve the inflammation-asso-
ciated symptoms, but also because they act as disease-mod-
ifiers [23]. Mechanistically, many of the anti-inflammatory 
effects of GCs can be traced back to their gene-repressive 
effect, targeting GR to key transcription factors which 
otherwise drive various inflammatory factors. however, 
upon chronic exogenous GC treatment, the associated side 
effects, such as diabetes, osteoporosis, and skin bruising 
and thinning, remain cumbersome [24]. In that respect, 
insulin resistance, and diabetes in particular, and also other 
side effects, are considered to arise mainly from the trans-
activation function of GR. Consequently, the impetus to 
develop novel selective GR modulators (SGRM) has never 
been stronger [25, 26]. Dissociating GR functionalities to 
improve therapeutic benefit is a concept that has further-
more been supported by gene-targeting experiments: trans-
genic mice with a dimerization-defective GR deficient in 
DNa binding still demonstrate functional transrepression 
and a GC-mediated anti-inflammatory response [27, 28]. 
Synthetic steroidal ligands for GR allowing a separation of 
GR-dependent transactivation and transrepression capaci-
ties in vitro, have not always maintained this characteristic 
in vivo [29]. In contrast, non-steroidal GR ligands, includ-
ing aL-438, ZK216348, ZK245186, LGD5552, and Com-
pound a (Cpda), have met these requirements with greater 
success in inflammatory animal model studies, although 
only a few of those have passed the pre-clinical stage 
(reviewed in [25, 26]).
Using genetic mouse models, a role for JNK2 activity, 
as controlled via a GR dimerization-dependent mechanism, 
has recently been implicated in the protection against sys-
temic tNF-induced lethal inflammation [30]. this finding 
indicates that a selection towards GR-mediated monomeri-
zation might not always be beneficial, and supports a con-
tributory role for GC-induced anti-inflammatory proteins, 
including MaPK phosphatase MKP-1 (encoded by the 
Dusp1 gene) in resolving inflammation in vivo [30]. On 
the other hand, the recent finding that dimerization-defec-
tive GR mutants could still retain dimerization capacities 
in vitro questions the extent of the receptor’s dissociative 
properties and hence challenges the transactivation ver-
sus transrepression model [31, 32]. however, it is as yet 
unclear to what extent and onto which specific promot-
ers a dimerization may still proceed in vivo. Nonetheless, 
an attempt to favor immuno-modulatory effects over the 
potential scala of side effects, the restriction of GR signal-
ing to well-defined pathways remains a valid strategy. as 
such, the exploration of differences and parallels between 
the GR-mediated transrepression of key inflammatory tran-




Murine L929sa fibrosarcoma cells were maintained in 
DMeM (Gibco-Invitrogen, Merelbeke, Belgium) sup-
plemented with 5 % fetal and 5 % newborn calf serum 
(International Medical Products, Brussels, Belgium), 
while human a549 lung epithelial cells were maintained in 
DMeM supplemented with 10 % fetal calf serum. to both 
culture media, 100 U/ml penicillin and 0.1 mg/ml strepto-
mycin (Sigma-aldrich, St. Louis, MO, USa) was added.
Mice
C57BL6/J mice were purchased from Janvier (Le Genest-
St Isle, France). JNK-2−/− mice had a C57BL6/J back-
ground and were purchased from the Jackson Laboratory 
(Bar harbor, Ma, USa). Mice were kept in individually 
ventilated cages under a dark-light cycle of 12 h each in a 
conventional animal house and received food and water ad 
libitum. all mice were used at the age of 8–12 weeks.
Plasmids
the full-size IL-6 promoter reporter gene construct 
p1168hu.IL6P-luc and the point-mutated variant p1168 
(aP-1 mut).IL6P-luc were previously described [33]. 
the reporter gene plasmid paP1-luc was purchased from 
Stratagene Cloning Systems (La Jolla, Ca, USa). the 
reporter gene plasmid p(IL6-κB)3-50hu.IL6P-luc has been 
described before [34] and the β-Gal-expressing plasmid to 
control for transfection efficiencies in transient transfection 
assays and/or cellular viability upon inductions was a kind 
gift from Dr. a. Liberman (University of Buenos aires, 
Buenos aires, argentina). the pCollagenase-3-luc reporter 
gene plasmid was a kind gift from Dr. e. Canalis (Saint 
Francis hospital and Medical Center, hartford, Connecti-
cut, USa).
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Cytokines, reagents, and antibodies
Dexamethasone (DeX) and 12-O-tetradecanoylphorbol-
13-acetate (tPa) were purchased from Sigma-aldrich. 
Recombinant mouse tNF was produced in E. coli and puri-
fied to homogeneity in our laboratories. tNF had a specific 
activity of 1.2 × 108 IU/mg and had no detectable endo-
toxin contamination. the preparation of luciferase (luc) 
reagent was described previously [33]. the origin, handling 
and storage of Cpda was previously described [35]. Stau-
rosporine (StS) was purchased from Calbiochem–Nova-
biochem International (San Diego, Ca, USa). Luciferase 
(luc) assays were carried out according to the protocol 
of Promega Corp. (Madison, WI, USa). Control experi-
ments showed that the final quantities of organic solvent 
used did not interfere with any of the assays. Normaliza-
tion of luc activity, expressed as arbitrary light units, was 
performed by measurement of β-galactosidase (β-gal) lev-
els in a chemi-luminescent reporter assay Galacto-Light 
kit (tropix, Inc., Bedford, Ma, USa). Light emission was 
measured in a luminescence microplate counter Victor Wal-
lac (Perkin-elmer, Cambridge, UK).
the phospho-specific p38 (thr-180/tyr-182), p42/p44 
(thr-202/tyr-204), and SaPK/JNK (thr-183/tyr-185) 
MaPK polyclonal rabbit antibodies detecting only the dual 
phosphorylated form of MaPK, and their non-phospho-
counterparts were purchased from Cell Signaling technol-
ogy (Beverly, Ma, USa). the same company also supplied 
the phospho-c-Jun (Ser-73) antibody and the anti-rabbit 
and anti-mouse IgG coupled to horseradish peroxidase, the 
latter of which was used as a second antibody for Western 
blotting. additional secondary antibodies, Goat anti-rabbit 
IgG (h + L) Dylight 800 conjugated (#35571) and Goat 
anti-mouse IgG (h + L) Dylight 680 conjugated (#35518) 
to use for development with the Odyssey (LI-COR, Lin-
coln, Ne, USa) were obtained from thermo Scientific. the 
MaPK analyzes itself were performed as described before 
[36]. the NF-κB p65, IκBα, and c-Jun antibodies were 
purchased from Santa Cruz (Santa Cruz Biotechnology, 
Santa Cruz, Ca, USa), the actin antibody was acquired via 
Sigma (Irvine, UK).
transfections
Stable transfections of L929sa cells were described pre-
viously [33]. L929sa cells were transiently transfected 
by a standard calcium phosphate coprecipitation protocol. 
Briefly, 105 actively growing cells were seeded in a 24-well 
plate 24 h before transfection. at day 0, 400 ng of total 
DNa was transfected. Sixteen hours post-transfection the 
medium was replaced with fresh medium and cells were 
left to rest for another 24 h, after which inductions were 
performed as indicated in the figure legends. Cells were 
lysed with lysis buffer (tropix, Inc., Bedford, Ma, USa), 
and samples were assayed for their β-gal content and lucif-
erase activity.
Injections and sampling
For the mice experiments, tNF was diluted in pyrogen-free 
phosphate-buffered saline (PBS) and all injections were 
given intraperitoneally (i.p.). Blood was withdrawn with a 
glass capillary from the retro-orbital plexus and after clot-
ting (overnight at 4 °C) serum was collected upon centrifu-
gation. to sample liver tissue, mice were killed by cervi-
cal dislocation, liver was isolated and stored in RNa later 
(Qiagen Benelux bv., Venlo, the Netherlands) before RNa 
preparation using an RNeasy Mini kit (Qiagen Benelux bv., 
Venlo, the Netherlands) according to the manufacturer’s 
instructions. all animal experiments were approved by 
the institutional ethics committee for animal welfare at the 
Faculty of Sciences, Ghent University.
GR knockdown
the targeting siRNa for GR knockdown species-specific 
siGR (siGeNOMeSMaRtpool NR3C1) and non-tar-
geting control (siControl) were purchased via Dharma-
con (thermo Fisher Scientific, Lafayette, CO, USa). the 
siRNa was transfected into L929sa cells and a549 cells as 
described previously [37, 38]. Subsequent to the indicated 
inductions, total RNa was isolated using tRIzol Reagent 
(Invitrogen, Carlsbad, Ca,USa). RNa samples were ana-
lyzed via Rt-qPCR as described below. Control protein 
samples of L929sa cells were analyzed via Western blot 
analysis, as described [37].
qPCR analysis
Following the treatment, as described in the figure legend, 
total RNa was isolated using tRIzol reagent (Invitrogen, 
Carlsbad, Ca, USa) following the manufacturer’s instruc-
tions. RNa concentrations of samples were determined and 
500 ng RNa was used in a Rt-step with MMLV reverse 
transcriptase (Promega, Madison, WI, USa) to produce the 
respective cDNa. Subsequently, the obtained cDNa was 
assayed for the gene expression levels of human GR, IL-6, 
IL-8, or c-jun (for a549 cells) or murine GR, IL-6, c-jun, 
tNF, DUSP1, MMP13, tIMP1, MCP1, IκBα or MCP-1 
for L929sa cells and/or murine samples) and at least two 
household gene levels as determined via Genorm [39] via 
qPCR in an ICycler (Bio-Rad, hercules, Ca, USa) using 
Sopachem reagents (Sopachem, eke, Belgium) or a Light-
cycler 480 System using Lightcycler 480 SYBRGreen I 
Master reagents (Roche Diagnostics, Vilvoorde, Belgium). 
Primer sequences used are readily available upon request.
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agilent array data analysis
after a starvation period of 24 h in DMeM devoid of 
serum, a549 cells were pretreated for 1 h with solvent, 
DeX (1 μM) or Cpda (10 μM), either or not followed by 
3-h treatment with tNF (2,000 IU/ml). total mRNa was 
isolated with tRIZOL (Invitrogen, Carlsbad, Ca, USa) 
and purified with a RNeasy kit (Qiagen Benelux bv., 
Venlo, the Netherlands), according to the manufacturers’ 
instructions. cDNa was labeled and amplified to cRNa for 
hybridization with the LowInput Quickamp Labeling Kit 
two-Color from agilent technologies (Diegem, Belgium). 
the hybridized and washed probes on each glass slide 
were scanned by an agilent DNa microarray scanner with 
Surescan high-Resolution technology and digital data 
extracted by agilent’s Feature extraction software 10.7.1.1 
(agilent). all treatments were performed in triplicate. the 
control condition was considered as a common reference.
Gene expression data were analyzed using the BioCon-
ductor [40] package “LIMMa” (ver. 3.6.1) [41] in the R 
statistical programming environment (ver. 2.12.0) [42]. a 
quality-control step was performed to increase the power 
of differential expression analysis by identifying meas-
ures from lower reliability spots. two measures were used 
as lower quality markers (i.e., “gIsPosandSignif” column 
provided by agilent scan software and the signal/noise 
ratio). Spots flagged as bad in every array were removed 
from the analysis.
Preprocessing was performed without background sub-
traction, as it was found to best keep correlation between 
replicates. Within-array normalization was performed 
using “loess” algorithm and between array normalization 
was performed using “aquantile”. entrez Gene IDs were 
assigned to the corresponding agilent probe ID, using the 
Bioconductor annotation package “hgug4112a.db” ver. 
2.4.5 [43]. Non-specific filtering was obtained by removing 
spots without an entrez Gene ID annotation. In addition, 
spots that didn’t reach at least 3 times (i.e. one condition) 
an expression level of 150 were removed. this left 22446 
probes for analysis.
a linear model was built for every condition and 
included a dye effect to account for any gene-wise dye 
bias. Contrasts were used to extract differently expressed 
genes between the following conditions: “a vs. Ctrl”, 
“tNF vs. Ctrl”, “a+tNF vs. Ctrl”, “a+tNF vs. tNF”, 
“Dex vs. Ctrl”, “Dex+tNF vs. Ctrl”, “Dex+tNF vs. 
tNF”, “a+tNF vs. Dex+tNF”. a correction for multiple 
hypothesis testing was performed on p values prior to gene 
selection using Benjamini and hochberg’s algorithm. Sig-
nificant spots were selected on the basis of a false discov-
ery rate adjusted p value cut-off of 0.05. In case multiple 
spots on the microarray were related to the same gene, only 
the most significant spot, corresponding to the highest F 
statistic, was selected for further analysis. this resulted in 
13,944 genes analyzed. the gene list for comparative anal-
ysis was built by selecting genes significant (p < 0.05) in 
at least one contrast of interest (including “tNF vs. Ctrl”, 
“DeX/tNF vs. tNF”, “Cpda/tNF vs. tNF” contrasts) 
and restricted to genes presenting a fold change of 1.3 in at 
least one contrast of interest.
For the generated gene lists, the promoter sequences 
(−450 bp to +50 bp) were analyzed for statistically sig-
nificant (p < 0.05) overrepresented transcription factor 
binding motifs of the Jaspar database by Pscan [44–46] and 
displayed NF-κB and aP-1 family members. additionally, 
the generated gene lists were also analyzed via ingenuity 
pathway analysis (IPa). each group was used as an input 
set for the “Core analysis” with default settings, except: 
Reference set = Genes only; Relationship = Direct; Confi-
dence = experimentally observed.
Chromatin immunoprecipitation (ChIP)
L929sa cells were starved in 0 % DMeM for 48 h. after 
the appropriate inductions, cells were subjected to a ChIP 
assay using an antibody against the GR (h-300, Santa 
Cruz). the ChIP analysis itself was performed as previ-
ously described [47]. DNa was purified using a QiaQuick 
purification kit (Qiagen Benelux bv., Venlo, the Nether-
lands). the amount of sonicated protein–DNa complexes, 
present before immunoprecipitation (IP), is measured in 
the input controls. Purified DNa samples, enriched with 
the immunoprecipitated protein and input controls, were 
subjected to qPCR in triplicate. Subsequently, the data 
obtained for immunoprecipitated samples were corrected 
for the respective signal from input control. to allow ratio 
comparisons, relative recruitment (Bound/Input) of the Sol-
vent condition was set at 1 and all other conditions were 
recalculated accordingly.
eLISa
Murine IL-6 eLISa was performed using a kit from Bio-
source (Invitrogen, Merelbeke, Belgium) for cellular 
media. IL-6 protein levels in in vivo samples were assayed 
using a 7tD1 bioassay [48].
Statistics
Statistical significance on averaged results of minimally 
two independent experiments was determined using one-
way aNOVa tests followed by a tukey multiple compari-
son post test or, for the in vivo analyses, via an unpaired 
t test. Survival curves (Kaplan–Meier plots) were compared 
by logrank test. Values as of p < 0.05 were considered 
significant.
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Results
Cpda favors selective GR transrepression of NF-κB  
in the human IL-6 promoter
a full IL-6 gene promoter activity results from a con-
certed cooperation between aP-1, CReB, C/eBP, and 
NF-κB transcription factors [12]. NF-κB has previously 
been described as a key transcription factor driving tumor 
necrosis factor (tNF)-induced IL-6 promoter activity [12]. 
Figure 1a shows the regulation by tNF in the absence or 
presence of dexamethasone (DeX) or the dissociated GR 
modulator Compound a (Cpda) of the wild-type human 
IL-6 gene promoter (a 1,168-bp fragment upstream of 
the transcription start site), stably transfected in L929sa 
murine fibroblast cells. as expected, DeX efficiently 
blocks tNF-induced IL-6 gene expression (Fig. 1a). In 
contrast, Cpda only marginally represses the tNF-induced 
IL-6 promoter activity in L929sa cells (Fig. 1a). this mod-
est inhibition is consistently observed (see also Fig. 2a). 
Upon mutating the aP-1 element, which is present within 
300 bp preceding the transcription start site in the IL-6 pro-
moter, both the tNF inducibility of the promoter, and the 
extent of promoter inhibition by DeX remain similar as for 
the wild-type construct (Fig. 1b). however, efficient repres-
sion is now also reached with Cpda (10 μM), comparable 
to the repression level that is obtained using DeX (Fig. 1b). 
this result suggests an inability of Cpda-activated GR to 
target the aP-1 element of the tNF-induced wild-type IL-6 
promoter.
the inhibitory effect of activated GR on NF-κB is a 
well-known phenomenon [49]. to additionally verify 
whether Cpda targets NF-κB to the same extent as DeX, 
we tested their ability to repress a tNF-induced solely 
NF-κB-driven recombinant promoter construct, carrying a 
minimal IL-6 promoter-derived tata box coupled to lucif-
erase. From Fig. 1c, and in contrast to the wild-type IL-6 
promoter, it is clear that both Cpda (10 μM) and DeX 
(1 μM) efficiently block the tNF-induced NF-κB-driven 
promoter construct (IL6κB)350hu.IL6P-luc+. these results 
suggest that Cpda-bound GR does not target aP-1 for tran-
srepression in fibroblast cells.
a strong aP-1-activating signal driving the IL-6 promoter 
does not concur with an efficient transrepression  
by Cpda-activated GR
It has been shown before that high inducibility of the IL-6 
promoter by the protein kinase inhibitor staurosporine (StS) 
involves the aP-1, CReB, and C/eBP class of transcription 
factors [12]. Interestingly, an inducible IL-6 gene expres-
sion by mediation of either NF-κB or aP-1 can be distin-
guished by activation of separate signaling pathways, which 
can synergize when stimulated simultaneously. Synergistic 
stimulation of the IL6-promoter has previously been dem-
onstrated upon combined treatment of StS and tNF [12]. 
In accordance with our earlier results [36], DeX efficiently 
blocks synergistic IL6 promoter stimulation by NF-κB and 
aP-1 (Fig. 2a). In sharp contrast, Cpda fails to mediate an 
efficient transrepression response (Fig. 2a). Combined StS 
a b c
Fig. 1  Cpda-mediated transrepression of the IL-6 gene promoter in 
fibroblast cells is only efficient in absence of a functional aP-1-re-
sponse element. a, b Subconfluent L929sa cell monolayers stably 
transfected with the indicated promoter reporter gene constructs were 
grown in 24-well plates. the point-mutated variant is indicated by its 
mutated transcription factor-binding site, i.e., aP-1, between brack-
ets. c Similar to panels (a) and (b), but with inductions performed 
on L929sa cells with a stably integrated recombinant (IL6κB)350hu.
IL6P-luc+ reporter construct. Cells were left untreated or treated with 
2,000 IU/ml tNF, for 5 h, preceded by a 1 h treatment with solvent 
(as indicated by the minus sign), DeX (1 μM) or Cpda (1 or 10 μM). 
at the end of the induction, cell lysates were assayed for reporter gene 
activities. total solvent concentration was kept similar in all condi-
tions. the experiments are carried out in triplicate or quadruplicate. 
Results are shown ± SD and are representative of two to four inde-
pendent experiments. **p < 0.01, ***p < 0.001. For (a) comparisons 
versus the control lane are depicted by ‘#’ and comparisons versus the 
respective pro-inflammatory stimulus tNF are depicted by ‘§’. For b 
and c, comparisons were made vs. tNF
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and tNF-induced IL-6 mRNa levels were only margin-
ally affected by Cpda, but efficiently downregulated in the 
presence of DeX (Fig. 2b). By additionally measuring the 
corresponding endogenous IL-6 protein levels via eLISa 
(Fig. 2c), we further established that the regulation of IL-6 
protein expression reflects the transcriptional regulation of 
the IL-6 gene promoter in terms of its inducibility, and also 
its transrepression capability, using DeX or Cpda (Fig. 2b, 
c). Whereas DeX is able to inhibit a massive IL-6 produc-
tion, which was instigated by a combined treatment with 
StS and tNF, to near baseline levels, Cpda (10 μM) only 
moderately inhibits this IL-6 protein production (Fig. 2c). 
Similar results were obtained when cells are stimulated with 
StS and tNF for 24 h (data not shown). By performing a 
dose response experiment using L929sa cells with a stably 
integrated (IL6κB)350hu.IL6P-luc+ plasmid, we verified 
that the highest dose of Cpda inhibited the combined StS 
and tNF-induced NF-κB-dependent reporter gene activ-
ity (Online Resource 1) equally well as the tNF-induced 
NF-κB-dependent reporter gene activity (Fig. 1c), i.e., near 
baseline levels. this result suggests that the selectivity of 
Cpda to transrepress NF-κB is largely independent of the 
nature of the NF-κB-activating stimuli.
In contrast to DeX, Cpda does not transrepress 
aP-1-driven promoter activity
the above results prompted us to take a closer look at addi-
tional aP-1 repression models with Cpda. to this purpose, 
we used a recombinant aP-1-driven reporter gene con-
struct, paP-1-Luc, transiently transfected in L929sa. addi-
tionally, to show that the divergent regulation by Cpda and 
DeX was unrelated to the nature of the NF-κB and aP-1 
stimuli, we changed stimuli into tPa treatment and com-
binations of StS with tNF or StS with tPa. a combined 




Fig. 2  activation of IL-6 expression parameters by combined NF-
κB- and aP-1-activating stimuli is repressed by DeX, but to a lesser 
extent by Cpda. a Subconfluent L929sa cell monolayers, stably 
integrated with the p1168hu.IL6P-luc+ reporter gene construct, 
were left untreated or treated with 2,000 IU/ml tNF, with 60 nM 
StS or a combination hereof, for 5 h, preceded by a 1-h treatment 
with solvent, DeX (1 μM) or Cpda (1 or 10 μM). at the end of 
the induction, cell lysates were assayed for reporter gene activities. 
the experiment was carried out in quadruplicate, and the results are 
representative of three independent experiments. ***p < 0.001. Com-
parisons versus the control lane are depicted by ‘#’, comparisons 
versus the respective pro-inflammatory stimuli are depicted by ‘§’. 
b L929sa cells, starved for 48 h in DMeM devoid of serum, were 
pre-incubated with solvent, DeX (1 μM), or Cpda (1 or 10 μM) for 
1 h, before StS (60 nM) and tNF (2,000 IU/ml) were added, where 
indicated, for 6 h. total RNa was isolated and subjected to Rt-qPCR 
assaying IL-6 and two household gene mRNa levels. Specific signal 
for cDNa of IL-6 was normalized to the averaged household genes 
signal. the StS/tNF condition was set as 100 and all other condi-
tions were recalculated accordingly to allow ratio comparisons. total 
solvent concentration was kept similar in all conditions. Results are 
shown ± SD. Comparisons were made vs. StS/tNF. the experiment 
was carried out in triplicate, and the result are averages of two inde-
pendent experiments. c L929sa cells were induced as in b. Medium 
was collected to perform a murine IL-6 eLISa. Protein levels are 
presented as pg per ml. total solvent concentration was kept similar 
in all conditions. Results are shown ± SD. ***p < 0.001. Compari-
sons were made vs. StS/tNF
▸
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(Fig. 3a). In contrast to DeX, Cpda failed to transrepress 
StS-induced, tPa-induced, combined StS and tNF- or 
StS and tPa-induced aP-1 promoter activities (Fig. 3a). 
the aP-1-driven MMP13 gene, coding for the enzyme col-
lagenase3, has previously been described to be susceptible 
to GC repression [28]. although this MMP13 gene is reg-
ulated by a more complex aP-1-driven promoter, a simi-
lar regulation as for the minimal aP-1-driven promoter is 
still apparent when assaying pCollagenase3-Luc (Fig. 3b). 
Interestingly, Cpda did not only fail to transrepress aP-1 
driven promoter activity, but seemed actually to enhance 
the StS and StS/tPa-induced aP-1-dependent promoter 
activities (Fig. 3a, b). a stably integrated promoter vari-
ant of paP-1-Luc in L929sa cells yielded overall similar 
results in terms of a refractory transrepression with Cpda 
(Online Resource 2). It is clear that the divergent transre-
pression characteristics of DeX and Cpda are largely 
maintained across different aP-1-reporter gene models, 
regardless of the aP-1-activating stimuli. as a positive con-
trol for the functionality of Cpda, we assayed in parallel 
the effect of Cpda on a tNF-driven (IL6κB)350hu.IL6P-
luc+ promoter construct, stably integrated in L929sa cells. 
For each experiment, this yielded results that were similar 
to those presented in Fig. 1c.
Cpda, in contrast to DeX, sustains aP-1-induced gene  
and protein expression
to find out how Cpda may affect the transcriptional 
regulation of an endogenous aP-1-controlled gene, we 
next analyzed its effect on c-jun mRNa levels via qPCR 
analysis. Only DeX, but not Cpda, ensured an efficient 
transrepression of StS/tNF-induced c-jun mRNa levels 
(Fig. 4a) and a concomitant repression of c-Jun protein 
levels (Fig. 4b). at the c-Jun protein level, and oppo-
site to DeX, we also noted a slight upregulatory effect 
with Cpda alone (Fig. 4b). these results point to distinct 
effects of DeX and Cpda in regulating aP-1-mediated 
protein production. as a positive control for the func-
tionality of Cpda and to further explore potential differ-
ences in target gene regulations, we studied in parallel 
the mRNa regulation of a number of other genes with a 
role in inflammation, i.e., the tNFα gene, the chemokine 
gene MCP-1, and the anti-inflammatory gene coding for 
IκBα. From Fig. 4c it can be concluded that both Cpda 
(10 μM) and DeX (1 μM) are able to efficiently tran-
srepress the StS/tNF-induced levels of tNFα mRNa. 
a similar regulation could be noted for MCP-1 (Online 
Resource 3a).
the mRNa regulation of the anti-inflammatory IκBα 
gene (NFκBia) shows a good inducibility upon treatment 
with StS and tNF and is a target for transrepression by 
Cpda, but not DeX (Online Resource 3b). In line with the 
presence of a GR-responsive binding motif in the proxi-
mal promoter region of the IκBα gene [50], DeX alone 
was able to enhance basal levels of IκBα mRNa (Online 
Resource 3b). as reported before [34], the combination 
of a pro-inflammatory stimulus with DeX does not fur-
ther enhance mRNa expression levels of IκBα (Online 
Resource 3b). this result is most likely the net effect of 
a stimulatory signal on the GRe element, combined with 
an inhibitory signal on the NF-κB element. Finally, the 
dissociated character of Cpda-activated GR is confirmed 
by measuring mRNa levels of the standard GRe-driven 
GILZ gene, which is only elevated in the presence of DeX 
(Online Resource 3c).
a b
Fig. 3  aP-1-driven gene transcription is downregulated by DeX but 
not by Cpda. a, b Subconfluent L929sa cell transiently transfected 
with paP-1-Luc or pCollagenase-3-Luc were untreated or treated 
with 2,000 IU/ml tNF, with 60 nM StS, with 50 ng/ml tPa or a 
combination hereof, for 5 h, preceded by a 1-h treatment with solvent, 
DeX (1 μM) or Cpda (1 or 10 μM). at the end of the induction, 
cell lysates were assayed for reporter gene activities. the experiment 
was carried out in triplicate, and the results are representative of at 
least two independent experiments. total solvent concentration was 
kept similar in all conditions. Results are shown ± SD. *p < 0.05, 
**p < 0.01, ***p < 0.001. Comparisons were made vs. the respective 
pro-inflammatory stimuli
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to generalize the validity of our findings, we broad-
ened our gene analysis and meanwhile expanded to an 
alternative cell system and species. In that respect, we 
assayed human a549 lung epithelial cells via an agilent 
expression analysis. Results show that of 422 tNF-induc-
ible genes, 179 genes were repressed by DeX. From this 
gene pool, 58 genes were in turn also repressed by Cpda 




Fig. 4  Predominantly aP-1-regulated target genes are only transre-
pressed by DeX- and not by Cpda-activated GR, but promoter com-
plexity determines the final outcome. a, c L929sa cells, starved for 
48 h in DMeM devoid of serum, were pre-incubated with solvent, 
DeX (1 μM), or Cpda (1 or 10 μM) for 1 h, before StS (60 nM) 
and tNF (2,000 IU/ml) were added, where indicated, for 6 h. total 
RNa was isolated and subjected to Rt-qPCR assaying cellular c-jun, 
tNFα, and β-actin and hypoxanthine–guanine phosphoribosyltrans-
ferase (hPRt) household gene mRNa levels. Specific signal for 
cDNa of c-jun or TNFα was normalized to the averaged household 
genes signal. the StS/tNF condition was set at 100 and all other 
conditions were recalculated accordingly to allow ratio comparisons. 
total solvent concentration was kept similar in all conditions. Results 
are shown ± SD. the experiment was carried out at least in triplicate 
and the results are averages of at least two independent experiments. 
Results of the statistical analysis via aNOVa followed by a tukey 
multiple comparison post-test are shown for particular groups of inter-
est, in comparison to the StS/tNF group). b L929sa cells, starved 
for 48 h in DMeM devoid of serum, were treated with solvent, a com-
bination of StS (60 nM) and tNF (2,000 IU/ml) for 5 h in absence 
or presence of a 1 h pretreatment of DeX (1 μM) or Cpda (10 μM). 
total protein extracts were prepared in duplicate and subjected to 
Western-blot analysis to detect c-Jun protein. Detection of NF-κB 
p65 served as a loading control (Ctrl). the result is a representative 
of three independently performed experiments. d a549 cells, starved 
for 24 h in DMeM devoid of serum, were pretreated for 1 h either 
with solvent, DeX (1 μM) or Cpda (10 μM), either or not followed 
by a 3-h treatment with tNF (2,000 IU/ml). Gene expression levels 
of corresponding RNa samples were evaluated by a whole genome 
transcriptome agilent array (upper panel). Genes with adjusted p val-
ues lower than 0.05 in at least one contrast and a fold change higher 
than 1.3 were selected as significant. Pscan analysis with a minimal 
statistical significance of p < 0.05, indicates enrichment for specific 
transcription factor binding motifs in the corresponding gene promot-
ers. here, we mention the identified NF-κB and aP-1 family members 
in bold (lower panel)
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(Fig. 4d; Online Resource 4). exemplary gene expression 
profiles of either group are displayed in Online Resource 
5). analysis via the bioinformatics tool Pscan [44] of the 
tNF-stimulated and DeX and/or Cpda–repressed genes 
(Online Resource 4) with a focus on NF-κB and aP-1 fam-
ily members, furthermore showed a possible discrimination 
in promoter motifs between DeX and Cpda-targeted gene 
promoters, as gene promoters which contain a NF-κB fam-
ily member-recognizing motif can be induced by tNF and 
repressed by both DeX and Cpda, whereas the additional 
presence of an aP-1 transcription factor binding motif 
allows DeX repression, but not Cpda repression.
to further support the Pscan analysis for enrichment of 
specific transcription factor-binding motifs, we performed 
an Ingenuity pathway analysis (IPa) on the tNF-upregu-
lated and DeX- and/or Cpda-downregulated gene sets, as 
listed in Online Resource 4, thus capturing the essence of 
the transcription factors regulated by DeX and Cpda. this 
analysis focuses on the enrichment of known NF-κB- and 
aP-1-regulated target genes in the dataset and shows that 
both NF-κB and aP-1 targets are highly overrepresented 
among tNF-stimulated genes that are repressed solely 
by DeX (table 1; Fig. 5a). In contrast, tNF-stimulated 
genes that are repressed by both DeX and Cpda or solely 
Cpda, show a relatively higher enrichment of NF-κB tar-
get genes as compared to aP-1 target genes (table 1; 
Fig. 5b–c). Indeed, even though SMG1, KIF1B PLat, 
FOSL1, PLaUR and CReB3L3, are not identified as NF-
κB-dependent target genes via IPa analysis in Fig. 5b, c, 
all of these gene promoters are marked by the presence of 
a binding motif for a NF-κB family member in their proxi-
mal promoter (table 2).
Combining these data, we conclude that in line with our 
hypothesis, all genes that are regulated by both DeX and 
Cpda, have been either previously identified as NF-κB tar-
gets or have a NF-κB family member binding site in their 
promoter (tables 1, 2; Figs. 4d, 5).
Cpda blocks eRK activation but sustains JNK activation 
in L929sa
the observation that a differential aP-1 regulation by DeX 
and Cpda may fine-tune GR transrepression efficacies is 
intriguing. In an attempt to find a plausible explanation for 
this phenomenon, we studied DeX- and Cpda-mediated 
regulation of MaPK activation patterns. In analogy with 
Table 1  enrichment of NF-κB and aP-1 target genes in a549 cells in the dataset as identified by IPa
Upstream regulator p value of overlap target molecules in dataset









NFκB (complex) 2.08e−05 CSF2,IL6,IL8,NFKB1,PtGS2,VeGFC
JUND 2.58e−05 BCL3,IL6,NR4a1,PLaU,SeRPINB9
FOS 3.44e−05 atF3,BCL2L11,eReG,FOSB,IL23a,IL6,IL8,JUN,PLaU,PLK2,PtGS2,SeRPINB9







Genes upregulated by TNF and exclusively downregulated by CpdA
ReLa 7.50e−12 CD40,CFB,ICaM1,IFNGR2,IKBKe,IL32,IRF1,NOD2,ReLa,Stat5a,tNFaIP2,tNIP1
NFκB1 1.31e−09 CD40,CFB,eBI3,ICaM1,IFNGR2,IKBKe,IRF1,NOD2,ReLa
NFκB (complex) 3.01e−06 CD40,CFB,CSF3,ICaM1,IRF1
JUN/JUNB/JUND 1.93e−02 CReB3L3
p values indicate the significance of overlap (Fisher’s exact test) between genes in the dataset and targets of the respective transcription factor
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previous findings [36], DeX does not block tNF-activated 
phospho-eRK MaPK in L929sa (Fig. 6a), and similar 
time-kinetics and results were noted for StS/tNF-activated 
phospho-eRK MaPK (Fig. 6b), suggesting that a different 
MaPK-activating signal does not lead to a different regu-
lation by GCs. In contrast to DeX, Cpda impedes both 
Fig. 5  Graphical illustration 
of differentially regulated 
aP-1 and NF-κB targets in 
the dataset. Arrows indicate 
experimentally confirmed 
promoter binding or regulation 
of expression. transcription fac-
tors are depicted in red and their 
respective target genes are dis-
played in green. Only subunits 
with at least one unique target 
were kept to avoid redundancy. 
Promoter analysis of the six tar-
gets with no known dependency 
on NF-κB (b and c) revealed 
the presence of NF-κB motifs, 
indicating possible contribution 
of this transcription factor to 
their transcriptional regulation 
(2000–2013 Ingenuity Systems, 
Inc. all rights reserved)
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the tNF and StS/tNF-induced phosphorylation of eRK 
MaPK (Fig. 6a–b).
JNK activation in L929sa cells was found to be very 
weak, using either tNF or StS/tNF. however, Cpda pro-
longs both tNF and StS/tNF-induced activation of JNK 
beyond the 15-min time point (Fig. 7a). Of note, the persis-
tent phosphorylation of JNK MaPK in presence of Cpda, 
is reflected in a similar phosphorylation profile of the 
downstream JNK target, c-Jun (Fig. 7b) and contrasts with 
the regulation by DeX. Finally, neither DeX nor Cpda can 
differentially modulate the p38 MaPK phosphorylation 
profiles (Online Resource 6). altogether, the observed dif-
ferential effects on c-Jun phosphorylation may explain why 
classic aP-1-driven gene expression remains unaffected or 
could be even slightly enhanced by Cpda-loaded GR, but 
is on the other hand readily repressed by DeX-activated 
GR (Figs. 3, 4a; Online Resource 4 and 5).
GR is essential to mediate the gene expression modulation 
effect of DeX and Cpda
to investigate whether our observations occur in a GR-
dependent or -independent manner, we used siRNa in 
L929sa fibroblasts. Controls via assaying GR mRNa levels 
via qPCR and GR protein levels via Western blot (Fig. 8a) 
revealed an efficient GR knock down of nearly 75 %. Firstly, 
we analyzed whether the presence of GR is pivotal to the 
effect of Compound a on JNK phosphorylation. Knockdown 
of GR in L929sa cells shows that a diminishment in GR pro-
tein can partially revert the negative impact of DeX on StS- 
and tNF-stimulated JNK phosphorylation, suggesting a GR 
dependence. however, a decline in GR protein levels does 
not seem to alter the positive effects of Compound a on sus-
taining this StS- and tNF-stimulated JNK phosphorylation 
Table 2  Presence of NF-κB family member motifs in promoters 
of FOS/JUN target genes (SMG, KIF1B, PLat, FOSL1, PLaUR, 
CReB3L3), as identified via Pscan
Symbol Score Position Sequence Strand
SMG1 0.91 −239 GGGGatCtCCa –
KIF1B 0.88 −432 GGGGGtCaCCC +
PLat 0.86 −435 GGGGCaCCtCC +
FOSL1 0.84 −154 GGGGCtCCaCC +
PLaUR 0.81 −432 GGGGtttCaCC +
CReB3L3 0.82 −201 GGGGtaCCtCC –
Pscan analysis was run with the following setting: Organism: 
H. Sapiens; Scan region: −450/+50 b: Motif Database: Jaspar. the 
table shows a summary for hits of the NFκB1 motif (Ma0105.1)
a
b
Fig. 7  Cpda sustains activated JNK and c-Jun in fibroblasts. a, 
b L929sa cells, starved for 48 h in DMeM devoid of serum, were 
pretreated with solvent, 1 μM DeX, or 10 μM Cpda for 1 h, fol-
lowed by either or not tNF (2,000 IU/ml) or tNF combined with StS 
(60 nM) for the indicated time points (in minutes). Cell lysates were 
made and activated JNK (a) was detected using the phospho-specific 
JNK MaPK antibody and activated c-Jun (b) was detected using the 
phospho-specific c-Jun antibody. aspecific bands, non-phosphoryl-




Fig. 6  Cpda, but not DeX, blocks activated eRK in fibroblasts. a, b 
L929sa cells, starved for 48 h in DMeM devoid of serum, were pre-
treated with solvent, 1 μM DeX, or 10 μM Cpda for 1 h, followed 
by either or not tNF (2,000 IU/ml) (a), or tNF combined with StS 
(60 nM) (b), for the indicated time points (in minutes). Cell lysates 
were made and activated eRK was detected using the phospho-spe-
cific eRK MaPK antibody. aspecific bands, non-phosphorylated 
proteins, and/or NF-κB p65 served as a loading control (indicated as 
load control)






Fig. 8  GR is essential to mediate the gene expression modulation 
effect of DeX and Cpda. L929sa cells were transfected with siRNa 
control (siControl) or siRNa targeted at GR (siGR) and were allowed 
to rest for 48 h post transfection. In the 16-h period before induction 
or sampling, cells were starved in DMeM devoid of serum. a We con-
trolled for the efficiency of siRNa GR targeting. total RNa was iso-
lated and subjected to Rt-qPCR for GR mRNa levels and expression 
levels were normalized to housekeeping gene controls. the expres-
sion levels for GR (siControl) were set at 100 and the siGR condition 
was recalculated accordingly (left panel). Cell lysates were made and 
GR protein was visualized via Western-blot analysis (right panel). 
actin served as a loading control. b SiRNa-transfected L929sa cells 
(siControl or siGR) were pretreated with solvent, 1 μM DeX, or 
10 μM Cpda for 1 h, followed by either or not tNF (2,000 IU/ml) 
combined with StS (60 nM), for the indicated time points (in min-
utes). Cell lysates were made and activated JNK was detected using 
the phospho-specific JNK MaPK antibody. NF-κB p65 served as a 
loading control (indicated as load control). c–e SiRNa-transfected 
L929sa cells (siControl or siGR) were pre-incubated with solvent, 
DeX (1 μM), or Cpda (1 or 10 μM) for 1 h, before tNF (2,000 IU/
ml) and StS (60 nM) was added, where indicated, for 6 h. total RNa 
was isolated and subjected to Rt-qPCR for specific target genes, and 
expression levels in each treatment group were normalized to house-
keeping gene controls. Normalized mRNa levels for DUSP1 (c) was 
presented with the DeX (SiControl) set as 100 and all other condi-
tions were recalculated accordingly. Normalized mRNa levels for 
IL-6 (d) and MMP13 (e) were presented with the StS/tNF condition 
(siControl and siGR) set at 100 and all other conditions were recalcu-
lated accordingly to allow ratio comparisons. total solvent concentra-
tion was kept similar in all conditions. Results are shown ± SD. the 
qPCR was carried out at least in triplicate. Results are representative 
for two independent experiments
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(Fig. 8b), arguing for a possibly GR-independent regula-
tion. as JNK phosphorylation is targeted by the DUSP1 
phosphatase [51], we wondered how Cpda would effect the 
production of DUSP1 mRNa. as expected, Cpda does not 
stimulate the activation of the GRe-regulated DUSP1 gene 
promoter, while DeX in a GR-dependent manner does so 
(Fig. 8c). hence, the apparent absence of GR dependence in 
Cpda-mediated regulation of JNK phosphorylation might be 
explained by the lack of DUSP1 synthesis.
Upon investigating the StS- and tNF-stimulated IL-6 
gene expression, DeX-mediated repression of IL-6 can be 
reverted by knockdown of GR in both L929sa and a549 
cells (Fig. 8d Online Resource 7b). In Cpda-treated cells, 
this GR knockdown has only a limited effect on what is 
already a marginal repression profile in a549 cells, when 
compared to DeX (Online Resource 7b-c). however, a 
knockdown of GR resulted in a clear ablation of the stim-
ulatory effect of Cpda on StS/tNF-regulated MMP13 
gene expression in L929sa cells (Fig. 8e) and c-Jun gene 
expression in a549 cells (Online Resource 7d), indicating 
that for aP-1 regulated genes GR is necessary to mediate 
the Cpda-induced elevation of the StS and tNF-stimu-
lated gene expression. to summarize, the presence of GR is 
essential to mediate the gene regulatory effect of DeX and 
Cpda, but appears to be redundant for the Cpda-mediated 
prolongation of JNK phosphorylation.
Cpda, in contrast to DeX, does not support GR 
recruitment onto the aP-1-dependent c-jun gene promoter
the failure of Cpda to block JNK MaPK activation, in the 
presence of tNF or its combination with StS, may explain 
Cpda’s deficiency to inhibit aP-1-mediated transcription. 
to define whether Cpda-activated GR is still recruited onto 
aP-1-driven gene promoters under those conditions, we 
performed a chromatin immunoprecipitation (ChIP) analy-
sis for endogenous GR in L929sa cells, using a primer set 
proximal to the aP-1-binding sites in the c-jun gene pro-
moter. Figure 9a shows that DeX can enhance GR promoter 
occupancy at the above-mentioned c-jun gene promoter 
region. however, Cpda-activated GR does not show a sta-
tistically significant elevated recruitment at this gene pro-
moter. When studying the recruitment of GR near the NF-
κB-binding site of the IL-6 promoter (Fig. 9b), we observe 
that in absence of the pro-inflammatory stimulus StS/tNF, 
GR is equally well recruited onto the basal IL-6 promoter in 
presence of DeX (1 μM) or Cpda (10 μM). however, fol-
lowing aP-1 stimulation with StS/tNF, a more pronounced 
GR recruitment can be detected in presence of DeX as 
compared to Cpda. Nevertheless, the IL-6 promoter does 
still show an enhanced GR promoter occupancy in the com-
bined presence of Cpda and StS/tNF (Fig. 9b), presum-
ably because of transcription factor region overlaps.
JNK2 is involved in the Cpda-mediated sensitization  
to tNF toxicity
So far, our findings were restricted to cellular models of 
fibroblasts and epithelial cells. to expand the validity of our 
a
b
Fig. 9  Only DeX recruits activated GR to the c-jun gene promoter. 
a, b L929sa cells, serum-starved for 48 h in DMeM devoid of serum, 
were pretreated for 1 h with solvent, DeX (1 μM), or Cpda (10 μM). 
ensuing the indicated stimulation with tNF (2,000 IU/ml) combined 
with StS (60 nM) for 30 min, cells were lysed and total cell extracts 
were subjected to ChIP analysis and subsequent qPCR, detecting 
GR protein recruitment at the c-jun or IL-6 gene promoters. qPCR 
signal of immunoprecipitated c-jun or IL-6 promoter fragments is 
presented relative to input data. averaged results of at least two inde-
pendent experiments are shown ± SD. *p < 0.05; **p < 0.01, and 
***p < 0.001
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conclusions in vivo, we treated C57BL6/J mice with Cpda 
or DeX for 6 h, in absence or presence of 25 μg of tNF, 
and subsequently we analyzed liver mRNa levels for aP-1 
target genes, MMP13, TIMP1, (Fig. 10a) and c-jun (data 
not shown). We could demonstrate that Cpda treatment, in 
the presence of tNF, coincides with an increased MMP13 
expression, while for TIMP1 mRNa expression, Cpda does 
not affect the tNF-induced transcription. For c-jun, overall 
levels were unaffected by tNF, DeX, Cpda, or combina-
tions thereof (data not shown), probably indicating that the 
killing time point is suboptimal to detect a modulation of this 
gene.
to explore the functional relevance of our findings, 
we switched to an animal model of systemic inflamma-
tion. Recently, it has been shown that mice expressing a 
dimerization-defective GR (GRdim/dim) exhibit an increased 
sensitivity towards tNF lethality [30]. GR-mediated con-
trol of tNF-induced inflammation involves the induction 
of MKP-1. Moreover, in MKP1−/− mice, which exhibit a 
more pronounced sensitivity to tNF and thus tNF-induced 
lethality, the phosphorylation of JNK was enhanced. Since 
JNK2−/− mice showed significant protection against tNF-
induced lethality, JNK2 was identified as an essential 
player in in vivo inflammation as induced by tNF.
Since the present data demonstrate that Cpda leads to 
a sustained JNK/aP-1 activity in fibroblasts, we asked 
whether Cpda may aggravate tNF-induced lethality in 
vivo, via JNK2 activation. hereto, we injected wt mice 
and JNK2−/− mice i.p. with 25 μg tNF (a lethal dose) fol-
lowed by Cpda (8 mg/kg), the dose that was previously 
found to be effective in the mouse model for eae) and 
monitored survival. as hypothesized, Cpda sensitizes 
mice to tNF-mediated lethality, an effect that is coun-
teracted in JNK2−/− mice (Fig. 10b). Since IL-6 levels 
are a good indicator for tNF sensitivity [52] we assayed 
IL-6 serum protein levels. In tNF-treated wt mice, 
Cpda enhanced IL-6 serum levels (Fig. 10c), which cor-
relates with the observed enhanced lethality (Fig. 10b). 
In contrast, in a JNK2−/− background, IL-6 protein lev-
els remained largely unaffected by the addition of Cpda 
(Fig. 8c), which again is in concordance with the observed 
similar extent of survival (Fig. 10b).
Fig. 10  Cpda enhances 
tNF-induced aP-1-driven 
gene expression in vivo and 
JNK2-/- mice are resistant to 
the Cpda-mediated hypersensi-
tivity to tNF-induced lethality. 
a Wild-type C57BL6/J mice 
were injected i.p. with solvent 
or tNF (25 μg) for a total of 
6 h, in the presence or absence 
of DeX (10 mg/kg) or Cpda 
(8 mg/kg), which was adminis-
tered 30 min before the solvent 
(PBS) or tNF administration. 
Liver mRNa was assayed for 
levels of MMP13 and TIMP1. b 
Wild-type C57BL6/J mice and 
JNK2−/− mice were injected i.p. 
with solvent or tNF (25 μg) 
in the presence or absence of 
Cpda (8 mg/kg). Survival of 
wt (black lines, n = 13–16) 
and JNK2−/− mice (red lines, 
n = 14–15) was monitored for 
the indicated time points. c 
Serum IL-6 protein levels were 
measured in wt and JNK2−/− 
mice 6 h after the challenge 
with tNF (25 μg), in the pres-
ence of either PBS or Cpda 
(8 mg/kg). averages of 2 inde-
pendent experiments are shown 
for (a) and (b). ns not signifi-
cant; *p < 0.05; **p < 0.01
a
b c
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Discussion
a major challenge in nuclear receptor biology is the iden-
tification of ligands with a transcription factor and/or gene-
selective action, influencing diseases through the regula-
tion of a subset of target genes and not across their entire 
gene-regulatory repertoire [53]. NF-κB and aP-1 are known 
inflammatory mediators and thus well-described transcrip-
tion factor targets of classic GR-mediated transrepression. 
In the current work, we present data demonstrating that the 
GR modulator Cpda, besides its ability to dissociate tran-
srepression from transactivation, is able to also discrimi-
nate between repression modes of NF-κB and aP-1, with 
a pronounced preference for the inhibition of NF-κB. So 
far, most of the steroidal GR ligands described are capable 
of transrepressing both NF-κB and aP-1 [7, 54, 55]. We 
describe here that Cpda, in contrast to classic GCs, does not 
block but rather sustains aP-1-driven gene expression. the 
underlying mechanism most probably involves a differential 
modulation of the JNK kinase and an impaired recruitment 
of Cpda-activated GR onto aP-1-driven gene promoters. 
these findings are summarized in a model (Fig. 11).
Upon studying the activated IL-6 promoter, stably inte-
grated in L929sa fibroblast cells, we consistently observed 
a stronger inhibitory potential of GCs as compared to 
Cpda (Figs. 1a, 2). Reporter gene analysis results using 
the 1,168 bp IL-6 promoter element (Fig. 1a) were sup-
ported by IL-6 mRNa and protein expression data (Fig. 2b, 
c), confirming a less efficient transrepression capacity of 
Cpda as compared to DeX, on IL-6 in fibroblasts. these 
consistent observations lead us to hypothesize that Cpda 
may preferentially target only a subset of GR-targeted 
transcription factors in the IL-6 gene promoter. three dif-
ferent strategies were followed to corroborate the working 
hypothesis that Cpda may favor NF-κB repression over 
aP-1 repression. First, efficient Cpda-mediated GR tran-
srepression is restored in reporter gene experiments with 
an IL-6 gene promoter variant with a point-mutation in 
the aP-1 binding site (Fig. 1b). Second, and as reported 
before [35], the recombinant triple NF-κB-binding ele-
ment-containing promoter, flanking a 50 bp minimal IL-6 
promoter (p(IL6κB)350hu.IL6P-luc+), is equally respon-
sive to the inhibitory potential of Cpda and DeX (Fig. 1c; 
Online Resource 1). third, direct proof for impaired aP-1 
Fig. 11  Summarizing model for the transcription factor-selective 
action of Cpda versus DeX. the cytoplasmic GR is kept in a ligand-
receptive conformation by binding to chaperone molecules. Upon 
binding of either GCs or Cpda, the GR changes its specific confor-
mation and translocates into the nucleus. GC-bound GR can form 
a homodimer and as such binds to a palindromic simple GRe, thus 
propagating its classic transactivation mechanism. Conversely, Cpda-
bound GR cannot form homodimers and is therefore not able to bind 
a simple GRe or support transactivation. While GC-bound GR leaves 
p38 and eRK MaPK phosphorylations (almost equal to symbol) 
unaffected, it diminishes JNK MaPK phosphorylation (slanting down 
arrow). Stimulation with Cpda affects these MaPK phosphoryla-
tions differently, as it actually prolongs JNK MaPK phosphorylation 
(arrow) and sparks a decline in eRK MaPK phosphorylation (slant-
ing down arrow). also Cpda does not affect the level of p38 MaPK 
phosphorylation (almost equal to symbol). as expected from the dif-
ferential MaPK phosphorylation modulations, Cpda- and GC-bound 
GRs also show a differentiation in transcription factor targeting. GC-
bound GR is recruited onto NF-κB- and aP-1-driven gene promoters 
and is fully capable of transrepressing both NF-κB- and aP-1-driven 
gene expression. In contrast, Cdpa-bound GR can only bind to NF-
κB-driven gene promoters and not to aP-1-driven gene promoters. 
as such, Cpda-bound GR only supports transrepression of NF-κB-
mediated gene transcription, and not aP-1-mediated gene transcrip-
tion
159Selective transcription factor cross-talk by GR
1 3
repression by Cpda, was provided in cellular studies ana-
lyzing either recombinant or physiological aP-1-driven 
promoters (Figs. 3, 4a, b; Online Resource 2, 7d) and was 
additionally supported by transcriptomic studies (Figs. 4d, 
5; table 1; Online Resource 4 and 5) and by analyzing 
aP-1 target gene expression using liver tissue from mice 
injected with Cpda and tNF (Fig. 10a). Promoters regu-
lated by aP-1 elements, but not NF-κB elements proximal 
to the transcription start site, include those ensuring the 
expression of c-jun and matrix metalloproteinase mem-
bers (MMPs), including MMP13 (collagenase-3). Recom-
binant aP-1 regulated promoters, either transiently or 
stably transfected into L929sa cells and regardless of the 
activating stimuli, are not repressed by Cpda-bound GR, 
while their activity is efficiently inhibited by classic GC-
activated GR (Fig. 3; Online Resource 2). In accordance 
with the reporter gene assays, only DeX but not Cpda 
repressed the synergistic activation of c-jun mRNa levels 
(Fig. 4a), which is further corroborated by protein expres-
sion data for c-Jun (Fig. 4b). Similar results were obtained 
via a microarray analysis of an alternative cell line, namely 
a549 lung epithelial cells (Online Resource 5a, 7), arguing 
against a cell type-specific effect. In vivo results even dem-
onstrate a significant Cpda-mediated enhancement of the 
tNF-induced MMP13 gene expression in liver, correspond-
ing to in vitro results in L929sa cells (Fig. 8e). applying 
software for transcription factor binding site prediction [44] 
revealed a long list of well-known cytokine and chemokine 
promoters carrying a NF-κB- as well as an aP-1-responsive 
element (or multiple ones) in their promoter regions within 
450 bps of the transcription start site. examples hereof are 
the interleukins (IL-6, IL-8, IL-1β), tNF, MCP-1, COX-
2, e-selectin, and a20. a Pscan analysis of a549 tran-
scriptomics suggests an overall possibility to discriminate 
between Cpda and/or DeX responsiveness on the basis 
of featured transcription factor binding sites, in which the 
presence of aP-1- binding motifs seems to be an indica-
tion of an additional responsiveness to DeX, as compared 
to Cpda (Fig. 4d). IPa analysis zeroing in on NF-κB and 
aP-1-regulated target genes confirms the ligand-induced 
discrimination between these two transcription factors 
(tables 1, 2; Fig. 5).
the question arises as to whether the transcription fac-
tor-specific effects we report here for transrepression by 
Cpda versus DeX in fibroblast cells are a rigid and gen-
eral phenomenon. Gene promoter-specific effects (e.g., the 
identity of flanking residues, or the distance between regu-
latory elements thus influencing promoter looping effects) 
may probably play an additional and decisive role, since we 
observed that some cytokines that are indeed co-regulated 
by NF-κB and aP-1, still demonstrate an efficient transre-
pression by Cpda. hence, caution is warranted, as the pres-
ence of a potential aP-1 binding site does not always allow 
to predict insensitivity towards Cpda-mediated repression. 
exemplary, the tNF gene itself was efficiently repressed 
by Cpda (Fig. 4c, Online Resource 4), as was the MCP-1 
gene (Online Resource 3a). Similarly, in another study it 
was found that the tNF-induced MMP1 gene expression 
was as efficiently downregulated by DeX as by Cpda in 
synovial fibroblasts [56]. Conceivably, Cpda effects on 
other transcription factors may further modulate the global 
activity of endogenous gene promoters regulated by mul-
tiple GR-responsive transcription factors. In addition, cell 
or tissue-specific effects might also influence transcrip-
tional responses to Cpda. this phenomenon might explain 
why in fibroblasts only a marginal Cpda-mediated tran-
srepression is observed for tNF-induced IL-6 (Figs. 1a, 
2a), whereas in murine sera an enhanced IL-6 production 
is observed (Fig. 10c). the latter situation is of course the 
result of a combined effect on multiple tissues and circulat-
ing immune cells. In a recent study, Cpda could efficiently 
transrepress the MMP13 (collagenase-3) gene in MeF 
cells [57]; and in primary synovial cells and osteoblast 
cells, as well as in spinal cord tissue, Cpda could transre-
press IL-6 to the same extent as DeX [58]. however, in 
the same primary osteoblasts Cpda did fail, as expected, 
to efficiently suppress two other typical aP-1-driven genes, 
namely those coding for IL-11 and osteoprotegerin [58]. 
Literature reports confirm that Compound a can also nega-
tively affect IL-6 gene expression and protein production 
in various tissues and cell lines with varying efficiencies 
[35, 59–61]. We therefore speculate that both the promoter 
context and the origin of the cell line or cellular tissue may 
co-determine differential responses towards Cpda as com-
pared to classic GCs. Further studies in multiple cell sys-
tems are needed to unravel the underlying basis for these 
discrepancies.
Mechanistically, the paradoxical sustained aP-1 activ-
ity and inhibition of NF-κB activity by Cpda in fibro-
blasts, in contrast to repression of both aP-1 and NF-κB 
by DeX, might be explained by compound-specific effects 
on the MaPK activation profiles. Indeed, although Cpda 
efficiently blocks activated eRK in L929sa cells (Fig. 6), 
which corresponds with its inhibitory capacity on the 
downstream target NF-κB, it fails to inhibit JNK activation 
(Fig. 7a). On the contrary, in presence of Cpda, the acti-
vated JNK signal is even sustained and slightly enhanced 
(Fig. 7a). however, this prolongation and enhancement of 
JNK phosphorylation appears not to require the presence 
of GR (Fig. 8b). GCs are known to drive the expression of 
dusp1, coding for MKP-1, which can target the phospho-
rylation of JNK [51]. Cpda, however, does not readily 
support the upregulation of classic GRe-regulated genes 
(Online Resource 3c). this would also include the dusp1 
MaPK phosphatase, as demonstrated for L929sa fibro-
blasts (Fig. 8c), human a549 epithelial cells and in vivo 
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in murine lung [38] and primary microglial and astrocyte 
cultures [61], a result that may well correlate with a pro-
longed JNK MaPK activation, as observed here. however, 
as the Cpda-treated and inflammatory stimulated condi-
tions show a prolonged phosphorylation of JNK in com-
parison to the solvent-treated set of samples (Figs. 7a, 8b) 
additional effects should be at play here. Nevertheless, the 
presence of GR is essential to mediate the gene regulatory 
effect of DeX and Cpda in both L929sa fibroblasts (man-
uscript 8c-e) and a549 cells (Online Resource 7) for both 
IL6, IL8 and the aP-1 regulated c-Jun and MMP13.
although the in silico virtual docking analysis of the 
group of Budunova [62] modeled Cpda in the GR ligand-
binding pocket, we currently cannot exclude other modes of 
binding as the Cpda-bound GR structure has not yet been 
crystallized, or out-of-target effects. In that context, we 
recently observed that Cpda was able to efficiently block 
the tNF-induced phosphorylation of all three MaPK, p38, 
eRK, and JNK in primary human synovial fibroblasts in a 
GR-independent manner [63]. hence, a different cellular 
context is able to promote an entirely different outcome, 
with respect to MaPK regulation.
It has been reported before that DeX-activated GR is 
recruited onto aP-1-dependent promoters, as such contrib-
uting to transrepression [64, 65]. In accordance with the 
gene and protein expression analyzes of c-Jun, ChIP anal-
yses revealed that only DeX-activated GR but not Cpda-
activated GR was retrieved on the c-jun gene promoter 
(Fig. 9a). Nevertheless, both DeX and Cpda translocate 
cytoplasmic GR to the nucleus [35]. Furthermore, and in 
agreement with the findings of Rogatsky et al. for MMP-
13 (collagenase-3) in UO2S cells [65], we could verify that 
the occupation by c-Jun of the MMP13 (collagenase-3) or 
c-jun gene promoters was constitutive and unchanged fol-
lowing either activating or repressing conditions (data not 
shown). Based on the ChIP data for the c-jun gene pro-
moter (Fig. 9a), it is tempting to speculate that on the IL-6 
gene promoter the observed GR recruitment level may pri-
marily reflect the recruitment onto the NF-κB site, since the 
close proximity between the NF-κB and aP-1 sites in the 
IL-6 gene promoter does not allow to distinguish recruit-
ment onto either binding site alone.
We have described before that Cpda is a selective mod-
ulator of GR which favors monomeric GR formation and, 
as such, does not support classic GRe-mediated gene tran-
scription [35, 56]. We have shown here that Cpda is also 
able to differentiate between NF-κB- and aP-1-dependent 
transrepression. as an important physiological conse-
quence of marked differential targets in vivo, we observed 
an increased sensitivity towards tNF lethality with a Cpda 
treatment (Fig. 10b) as opposed to a treatment with DeX 
[30]. It is clear that in a hyperinflammatory context, Cpda 
is not able to inhibit IL-6 (as observed for fibroblasts in 
vitro), but on the contrary leads to an enhanced IL-6 pro-
tein production in vivo. In accordance with the in vitro data 
on JNK MaPK, and by using a JNK2−/− mouse model, we 
established a direct involvement of activated JNK, more 
specifically of JNK2, in the Cpda-mediated shift toward 
increased sensitivity to tNF.
to the best of our knowledge, this is the first report on 
a non-steroidal GR modulator capable of discriminat-
ing between NF-κB and aP-1 signaling in different cel-
lular contexts. Other groups have focused on identifying 
GR mutants with different transcription factor specificities 
[66–68]. earlier, different GR surfaces and/or mechanisms 
have been proposed to be involved in the repression of NF-
κB or aP-1, and cell-type restrictions have also been noted 
for the gene regulatory actions of GR point mutants [66]. 
the team of Okret characterized a GR point mutation in 
the DNa-binding domain (rat GR R488Q), which is able 
to distinguish between NF-κB and aP-1 repression, in this 
particular case favoring aP-1 transrepression [66]. taken 
together, the present data support the notion that GR may 
utilize different mechanisms to repress NF-κB as compared 
to aP-1.
In conclusion, a ligand for GR that selectively targets 
NF-κB and not aP-1 signaling pathways, not only narrows 
down the number (quantity) of affected targets and biologi-
cal processes but also the extent (quality) of affected targets 
and processes. hence, a discriminating compound, such as 
Cpda, is a very attractive tool to deepen our understanding 
of NF-κB- and aP-1-selective GR responses in specific tis-
sues. Given the surprising opposite effects to DeX in terms 
of survival in an aggressive model of systemic inflamma-
tion, our study additionally conveys the important message 
that GR modulators with a differential transcription factor 
targeting profile may potentially aggravate an inflammatory 
response instead of resolving it. It remains to be investi-
gated further whether the development of novel compounds 
with a similar level of selectivity may hold therapeutic 
promise, in specific clinical settings.
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